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Abstract The somatotropin release-inhibiting factor so-
matostatin-14 (SRIF) is known to activate distinct recep-
tor subtypes (sst1–5). In rat pituitary tumor cells (GC
cells), sst2 but not sst1 receptors mediate the SRIF-induced
inhibition of intracellular concentration of Ca2+ ([Ca2+]i)
and are negatively coupled to cAMP-dependent pathways.
In the present study, transduction mechanisms coupling
distinct SRIF receptors to their specific functional role
were investigated with the use of both SRIF agonists with
well-known affinity at individual SRIF receptors and the
sst2 receptor antagonist L-Tyr8 isomer of Cyanamid
154806 (CYN-154806). Our results demonstrate that sst1
and sst2 receptors are coupled to distinct signaling path-
ways in GC cells. In particular, sst2 receptors are nega-
tively coupled to the cAMP-dependent pathway and this
pathway is partially responsible for the sst2 receptor-me-
diated inhibition of [Ca2+]i. In addition, sst1 and sst2 re-
ceptors are both coupled to a decrease of arachidonic acid
(AA) release with an efficacy similar to that of SRIF, sug-
gesting that SRIF reduces AA release through either a
partial activation of both receptors or the activation of one
at a time. This finding is important given the well-ac-
cepted role for phospholipase A2 (PLA2) as a positive sig-
naling component in transduction pathways of SRIF re-
ceptors. sst1 and sst2 receptor negative coupling to
PLA2/AA pathways does not seem to be implicated in the
SRIF-induced inhibition of [Ca2+]i. The possible role for
the SRIF-mediated inhibition of AA release in GC cell
function remains to be elucidated.
Keywords Peptide receptors · Agonists · Antagonist ·
Intracellular Ca2+ · cAMP · PLA2/AA · Cell culture · 
Fluorimetry · Biochemical dosages · Somatostatin
Introduction
Rat pituitary somatotrophs exhibit spontaneous or stimu-
lated electrical activity associated with transient increase
of intracellular free calcium concentration ([Ca2+]i;
Kwiecien et al. 1997; Tomic et al. 1999a). The [Ca2+]i is
critical in the control of both basal and stimulated growth
hormone (GH) secretion (Tomic et al. 1999a, 1999b). So-
matostatin-14 (somatotropin release-inhibiting factor;
SRIF) is a naturally occurring hypothalamic tetradecapep-
tide (Brazeau et al. 1973) that inhibits rhythmic [Ca2+]i
transients (Kwiecien et al. 1997; Tomic et al. 1999b), thus
reducing GH release from pituitary cells (Tomic et al.
1999b).
In many cell types, SRIF controls [Ca2+]i by binding to
one or more individual SRIF receptor subtypes, named
sst1–sst5 receptors (for review see Patel 1999). In pituitary
cells, the SRIF receptors mediating SRIF action on [Ca2+]i
transients are not well characterized, although an involve-
ment of sst1, sst2 and sst5 receptors in the SRIF-induced
reduction of GH release has been demonstrated (Raynor
et al. 1993; Briard et al. 1997; Shimon et al. 1997;
Djordjijevic et al. 1998; Kreienkamp et al. 1999; Parmar
et al. 1999).
Growth Cells (GC cells) belong to a cell line derived
from a rat pituitary tumor (subclone of the GH3 strain). In
contrast to normal somatotrophs, they all exhibit sponta-
neous, rhythmic action potentials and concomitant oscilla-
tions of [Ca2+]i (Kwiecien et al. 1998) which, in turn, al-
low GH secretion. This process is inhibited by the appli-
cation of octreotide, a long-lasting SRIF agonist (Mounier
et al. 1995) that displays high affinity for sst2 receptors,
although it also binds to sst5 receptors (Raynor et al. 1993;
Siehler et al. 1998; Siehler and Hoyer 1999). Previous re-
sults have demonstrated that the membranes of GC cells
express distinct SRIF receptors and, in particular, sst1 and
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